Pacific Shuanglin Bio-pharmacy Co

Pacific Shuanglin Bio-pharmacy Co Interest Coverage

The Interest Coverage Ratio of Pacific Shuanglin Bio-pharmacy Co (000403.SZ) as of Oct 30, 2026 is 11.92. In the previous year, Interest Coverage Ratio was 14.99 — a change of -20.49% (lower).

Interest Coverage

11.92

YoY

-20.49%

Last updated:

Interest Coverage Ratio of Pacific Shuanglin Bio-pharmacy Co is 2024 11.92 . Interest Coverage Ratio of Pacific Shuanglin Bio-pharmacy Co was 2023 14.99 . It decreases by -20.49% lower compared to the previous year.

The Pacific Shuanglin Bio-pharmacy Co Interest Coverage history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Interest Coverage
Date
Interest Coverage
Jan 1, 2017
3.01 CNY
Jan 1, 2018
4.98 CNY
Jan 1, 2019
9.31 CNY
Jan 1, 2020
220.30 CNY
Jan 1, 2021
3.67 CNY
Jan 1, 2022
10.44 CNY
Jan 1, 2023
14.99 CNY
Jan 1, 2024
11.92 CNY
The Pacific Shuanglin Bio-pharmacy Co Interest Coverage history
YEARInterest CoverageYoY
11.92-20.49%
14.99+43.57%
10.44+184.72%
3.67-98.33%
220.30+2,266.09%
9.31+87.02%
4.98+65.47%
3.01+5.43%
2.85+29.48%
2.20-86.59%
16.43—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Pacific Shuanglin Bio-pharmacy Co Stock analysis

What does Pacific Shuanglin Bio-pharmacy Co do? Pacific Shuanglin Bio-pharmacy Co., Ltd. generates revenue through the production and marketing of pharmaceutical products including human albumin, intravenous immunoglobulin (pH4), human immunoglobulin, hepatitis B human immunoglobulin, tetanus immunoglobulin, and rabies immunoglobulin. The company targets domestic healthcare providers and hospitals within China as its primary customers. Its core business focuses on supplying essential therapeutic products for medical treatment and patient care. The firm operates exclusively within the domestic Chinese market without international expansion. The company's product portfolio consists of specialized immunoglobulins and blood-derived therapeutic agents. These products serve critical medical needs such as immune support, infection prevention, and treatment of specific diseases. Domestic hospitals and healthcare institutions are the primary buyers of these pharmaceutical solutions. The business model relies on consistent domestic demand for these specialized medical products. Pacific Shuanglin Bio-pharmacy's revenue streams are derived from the sale of its core pharmaceutical products to Chinese healthcare facilities. The domestic market remains the sole operational focus, with no indication of international sales or additional product lines beyond those listed. The company's workforce of 2,093 full-time employees supports this focused production and distribution model. Pacific Shuanglin Bio-pharmacy Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Pacific Shuanglin Bio-pharmacy Co stock

Interest Coverage Ratio of Pacific Shuanglin Bio-pharmacy Co is 11.92 in 2024.

Interest Coverage Ratio of Pacific Shuanglin Bio-pharmacy Co changed from 14.99 to 11.92, representing a -20.49% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Interest Coverage Ratio Pacific Shuanglin Bio-pharmacy Co since 2006 – with annual values, charts, and detailed analysis.

The Interest Coverage ratio measures a company's ability to pay interest on its debt. Higher ratios indicate greater financial strength and lower default risk.

Interest Coverage = EBIT / Interest Expense

A 'good' varies by industry and company stage. On Eulerpool, you can compare Interest Coverage Ratio's Pacific Shuanglin Bio-pharmacy Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Pacific Shuanglin Bio-pharmacy Co

All Key Metrics — Pacific Shuanglin Bio-pharmacy Co